Clinical trials recruiting in Farmington, Connecticut

Phase breakdown

Conditions recruiting in Farmington, Connecticut

Recruiting trials in Farmington, Connecticut

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
  NCT07238556 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female)
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female)
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
  NCT06667908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
  NCT06875960 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
  NCT06976268 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
  NCT05174351 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female)
• Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait
  NCT07083531 · Phase: Not specified · Ages: 50 Years and older · Sex: Female
• Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
  NCT00762008 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Circulating Markers for Ischemic Heart Disease
  NCT00762333 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Daily Amino Acid Supplementation for People With Parkinson's Disease
  NCT07115563 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 90 Years · Sex: All (male and female)
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Parkinson's Foundation PD GENEration Genetic Registry
  NCT04994015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• Pulmonary Hypertension Association Registry
  NCT04071327 · Phase: Not specified · Ages: 0 Years and older · Sex: All (male and female)
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of BHV-1400 in IgA Nephropathy
  NCT07054684 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
  NCT06701903 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Farmington, Connecticut?

25 recruiting trials have at least one study site in Farmington, Connecticut.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.